Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors and Its Role in Predicting Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

  • By

  • Jie Mei

  • Guanyu Jiang

  • Yundi Chen

  • Yongrui Xu

  • Yuan Wan

  • Ruo Chen

  • Feng Liu

  • Wenjun Mao

  • Mingfeng Zheng

  • Junying Xu

  • September 17, 2026

Share

Clinical Scorecard: Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors and Its Role in Predicting Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

At a Glance

CategoryDetail
ConditionNon-Small Cell Lung Cancer
Key MechanismsHLA-DRA as a marker for immuno-active tumors
Target PopulationPatients with Non-Small Cell Lung Cancer undergoing anti-PD-1 therapy
Care SettingOncology

Key Highlights

  • Correction of Fig. 5E due to duplication error
  • HLA-DRA identified as a potential biomarker
  • Study conclusions remain unchanged after correction

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with Non-Small Cell Lung Cancer

          Role of HLA-DRA in predicting response to anti-PD-1 therapy

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

            • by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

            • September 17, 2026

            Related Content

            Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

            CAR T Before Surgery Improves Glioblastoma Control in Mice

            Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

            • September 7, 2026

            • 3 min
            Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma